Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling

In conclusion, our findings support the concept that PD-L1/PD-1 blockade in CLL could be enhanced when combined with avadomide through the promotion of immunogenic IFN signaling that enhances T cell infiltration and function. We believe these data support the rationale for combination immunotherapy that could convert a non-immunogenic TME into a 'hot' T cell inflamed TME which would be sensitive to checkpoint blockade.DisclosuresHagner: Celgene Corporation: Employment, Equity Ownership. Towfic: Celgene Corporation: Employment, Equity Ownership. Gandhi: Celgene Corporation: Employment, Equity Ownership. Stamatopoulos: Abbvie: Honoraria, Research Funding; Gilead: Honoraria, Research Funding; Janssen: Honoraria, Research Funding. Patten: L Hoffman La Roche: Honoraria, Research Funding; Gilead Sciences: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel, Research Funding; AbbVie Inc: Honoraria, Other: travel; Janssen: Honoraria, Other: travel. Vardi: Gilead: Research Funding; Janssen: Honoraria. Ramsay: MedImmune: Research Funding; Roche Glycart AG: Research Funding; Celgene Corporation: Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Ioannou, N., Hagner, P. R., Towfic, F., Gandhi, A. K., Stamatopoulos, K., Patten, P. E. M., Vardi, A., Ramsay, A. G. Tags: 641. CLL: Biology and Pathophysiology, excluding Therapy: Overcoming Immunodeficiency in CLL Source Type: research